Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

The World Health Organization says the cost of developing new cancer treatments doesn’t seem to justify those drugs’ high prices, as the pharmaceutical industry argues.

The big picture: "The costs of R&D and production may bear little or no relationship to how pharmaceutical companies set prices of cancer medicines,” WHO officials said in a recent research paper.

The report says new cancer treatments have translated into better survival rates, but that high prices are the main factor limiting access to those life-saving drugs.

  • And it sharply contradicts the industry’s argument that those prices are necessary to recoup the cost of developing new drugs — including the money they spend on products that fail.
  • “Pharmaceutical companies set prices according to their commercial goals, with a focus on extracting the maximum amount that a buyer is willing to pay for a medicine,” the report says. “This pricing approach often makes cancer medicines unaffordable, preventing the full benefit of the medicines from being realized.”

The other side: “The report is wrong on the facts and deeply flawed,” a spokeswoman for the Pharmaceutical Research and Manufacturers of America said. “The report’s narrow scope fails to properly account for the value that cancer medicines provide to patients, health care systems and societies.”

  • And the WHO report does say that government price-setting doesn’t always work.
  • “In some countries, cost-containment measures ... have resulted in reduced, delayed and even cancelled treatment,” the report says.

By the numbers: Even after accounting for failed clinical trials and other opportunity costs, drug companies saw a median return of $14.50 for every $1 they spent on research and development, the paper says, citing earlier research published in the Journal of the American Medical Association.

  • By the end of 2017, 5 cancer drugs had each accumulated more than $60 billion in lifetime sales. (The top 3 are all manufactured by Roche, followed by Amgen and Novartis.)

The report also questions whether some new drugs are adding value commensurate with their price.

  • A product that extends a patient’s life by a few weeks or months, for example, means a lot to the patient but perhaps shouldn’t be priced like a bigger breakthrough.

The bottom line: “We’re spending a lot, but maybe we should expect more from those dollars that we’re spending,” said Stacie Dusetzina, a professor at the Vanderbilt University School of Medicine.

Go deeper

Updated 10 mins ago - Politics & Policy

Omicron dashboard

Illustration: Brendan Lynch/Axios

  1. Health: Transplants rebound from COVID lull
  2. Vaccines: WHO: No evidence that healthy children, teens need boosters — Kids' COVID vaccination rates are particularly low in rural America
  3. Politics: Government website for free COVID tests launches early
  4. World: Greece imposes vaccine mandate for people 60 and older
  5. Variant tracker
11 mins ago - Politics & Policy

Schumer pushes for doomed filibuster changes

Senate Majority Leader Chuck Schumer addressed reporters on Tuesday. Photo: Bill Clark/CQ-Roll Call, Inc via Getty Images

Senate Majority Leader Chuck Schumer told the Democratic caucus Tuesday night he plans to propose instituting a one-time "talking" filibuster requirement, and bypassing the 60-vote threshold for major legislation, to pass the party's election reforms package via simple majority.

Why it matters: While Schumer acknowledged both votes are expected to fail — and some vulnerable Democrats up for reelection feel it will put them in a tough spot — he argued it's worth putting members on the record for historic legislation.

Jan. 6 committee subpoenas Rudy Giuliani, Sidney Powell

Rudy Giuliani. Photo: Jeff Kowalsky/AFP via Getty Images

The House select committee investigating the Jan. 6 Capitol riot released its latest round of subpoenas on Tuesday evening, this time focusing on several of former President Trump's lawyers, including Rudy Giuliani and Sidney Powell, and former adviser Boris Epshteyn.

Why it matters: The panel said the four individuals subpoenaed were involved in efforts publicly promote Trump's unfounded claims of election fraud as well as efforts to "disrupt or delay" the certification of the election's results.